Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ASMB files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsAssembly Biosciences expands ABI-6250 into two new liver diseases, Phase 2 trials to start Q4 2026
Filed May 22, 2026 · Period ending May 22, 2026 · ~1 min read
Key Changes
-
high
Company expanding ABI-6250 drug candidate beyond hepatitis delta virus into primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), significantly broadening potential market opportunity into cholestatic liver diseases.
Item 8.01: Press Release verify on EDGAR → -
high
Phase 2 trial for hepatitis delta virus planned for Q4 2026, with separate Phase 2 basket study for PBC and PSC expected Q1 2027 pending regulatory feedback.
Item 8.01: Press Release verify on EDGAR → -
medium
Phase 1a data confirmed drug's mechanism of action through dose-dependent bile acid increases; completed chronic toxicology studies support longer-term dosing in upcoming trials.
Item 8.01: Press Release verify on EDGAR → -
medium
Pre-IND meeting with FDA described as constructive with helpful guidance for cholestatic disease development, though official meeting minutes still pending.
Item 8.01: Press Release verify on EDGAR →
Summary
Assembly Biosciences announced a major strategic expansion of its lead drug candidate ABI-6250, moving beyond its original target of chronic hepatitis delta virus infection into two additional cholestatic liver diseases: primary biliary cholangitis and primary sclerosing cholangitis. This expansion significantly broadens the commercial opportunity for the asset, as these conditions involve bile acid accumulation that drives liver damage—a mechanism the drug appears designed to address. The company has laid out a clear development timeline with Phase 2 trials for hepatitis delta virus starting in Q4 2026 and a basket study for the new indications beginning Q1 2027, subject to regulatory feedback.
Early Phase 1a data confirmed the drug works as intended by showing dose-dependent increases in bile acids, and completed toxicology studies support extended dosing periods needed for Phase 2 trials. Retail investors should watch for the official FDA meeting minutes and any updates on the Q4 2026 trial initiation. The success of this expansion strategy depends on whether ABI-6250's mechanism translates effectively across these different liver diseases, making the upcoming Phase 2 data critical milestones for validating the broader platform potential.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
Assembly Biosciences announces expansion of ABI-6250 clinical development into primary biliary cholangitis and primary sclerosing cholangitis.
Added in current filing · verify on EDGAR →
Assembly Biosciences, Inc. (the "Company") issued a press release announcing its plans to expand the clinical development of ABI-6250 ("6250"), its oral entry inhibitor candidate for chronic hepatitis delta virus ("HDV") infection, into primary biliary cholangitis ("PBC") and primary sclerosing cholangitis ("PSC"), broadening the program into cholestatic liver diseases.
The company is expanding its ABI-6250 drug candidate beyond its original indication for chronic hepatitis delta virus infection into two additional liver diseases: primary biliary cholangitis and primary sclerosing cholangitis. This broadens the potential market opportunity for the drug candidate into cholestatic liver diseases, which could increase the commercial value of the asset if clinical trials are successful.
Event · Item 8.01 — Other Events
Assembly Biosciences plans to expand clinical development of 6250 into PBC and PSC cholestatic liver diseases, with Phase 2 trials starting Q4 2026 and Q1 2027.
Added in current filing · verify on EDGAR →
The Company plans to initiate a Phase 2 clinical study of 6250 in HDV in the fourth quarter of 2026.
The company has set a specific timeline to begin Phase 2 testing of 6250 for HDV in Q4 2026. This represents advancement from the completed Phase 1a trial and provides investors with a concrete near-term clinical milestone to track.
Added in current filing · verify on EDGAR →
In addition, a Phase 2 basket study in cholestatic liver diseases, focused on PBC and PSC, is expected to begin in the first quarter of 2027, subject to regulatory feedback.
A Phase 2 basket study targeting both PBC and PSC is planned for Q1 2027, pending regulatory feedback. This timeline is contingent on regulatory input, introducing some uncertainty, but establishes the company's development roadmap for the expanded indications.
Added in current filing · verify on EDGAR →
The Company recently conducted a pre-IND meeting with the U.S. Food and Drug Administration to discuss the planned development of 6250 in cholestatic liver diseases. While official meeting minutes are pending, the Company believes the discussion was constructive and provided helpful guidance to support advancement of the program.
Assembly held a pre-IND meeting with the FDA regarding 6250 development in cholestatic diseases. The company characterizes the discussion as constructive, though official minutes are still pending. This suggests preliminary regulatory alignment, though formal confirmation is awaited.
Event · Item 9.01 — Financial Statements and Exhibits
Assembly Biosciences filed an 8-K attaching a press release dated May 22, 2026; no material event details disclosed in the filing body.
Added in current filing · view on EDGAR →
Exhibit | Number | Description | 99.1 | Press Release dated May 22, 2026.
The company attached a press release dated May 22, 2026 as Exhibit 99.1. The 8-K body does not disclose the content or subject matter of the press release, so the nature of the announcement cannot be determined from this filing alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 27, 2026 · How we verify